These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22496391)

  • 21. Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.
    Yi P; Hadden C; Kulanthaivel P; Calvert N; Annes W; Brown T; Barbuch RJ; Chaudhary A; Ayan-Oshodi MA; Ring BJ
    Drug Metab Dispos; 2010 Apr; 38(4):554-65. PubMed ID: 20075192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
    Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
    Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidation of 1,8-cineole, the monoterpene cyclic ether originated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and human liver microsomes.
    Miyazawa M; Shindo M; Shimada T
    Drug Metab Dispos; 2001 Feb; 29(2):200-5. PubMed ID: 11159812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin.
    Yamazaki H; Shimada T
    Drug Metab Dispos; 1998 Nov; 26(11):1053-7. PubMed ID: 9806945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin.
    Butrovich MA; Tang W; Boulton DW; Nolin TD; Sharma P
    J Clin Pharmacol; 2022 Aug; 62(8):1018-1029. PubMed ID: 35247279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolism of endosulfan-alpha by human liver microsomes and its utility as a simultaneous in vitro probe for CYP2B6 and CYP3A4.
    Casabar RC; Wallace AD; Hodgson E; Rose RL
    Drug Metab Dispos; 2006 Oct; 34(10):1779-85. PubMed ID: 16855053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/Pharmacodynamic modelling of Saxagliptin and its active metabolite, 5-hydroxy Saxagliptin in rats with Type 2 Diabetes Mellitus.
    Wang T; Tao T; Liu Y; Dong J; Ni S; Liu Y; Li Y; Xu N; Sun Z
    BMC Pharmacol Toxicol; 2024 Jun; 25(1):35. PubMed ID: 39103956
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
    Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
    Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Deacon CF; Holst JJ
    Adv Ther; 2009 May; 26(5):488-99. PubMed ID: 19444391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
    Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
    Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist.
    Ghosal A; Lu X; Penner N; Gao L; Ramanathan R; Chowdhury SK; Kishnani NS; Alton KB
    Drug Metab Dispos; 2011 Jan; 39(1):30-8. PubMed ID: 20926621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
    Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
    Drug Metab Dispos; 2024 Jun; 52(7):690-702. PubMed ID: 38719744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches.
    Gao J; Shi Z; Zhu S; Li GQ; Yan R; Yao M
    J Ethnopharmacol; 2013 Jan; 145(2):566-72. PubMed ID: 23207062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.
    McConn DJ; Lin YS; Allen K; Kunze KL; Thummel KE
    Drug Metab Dispos; 2004 Oct; 32(10):1083-91. PubMed ID: 15377640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists.
    Sanwald P; David M; Dow J
    Drug Metab Dispos; 1996 May; 24(5):602-9. PubMed ID: 8723743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
    Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
    Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Vitro Kinetic Characterization of Axitinib Metabolism.
    Zientek MA; Goosen TC; Tseng E; Lin J; Bauman JN; Walker GS; Kang P; Jiang Y; Freiwald S; Neul D; Smith BJ
    Drug Metab Dispos; 2016 Jan; 44(1):102-14. PubMed ID: 26512042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and Disposition of Siponimod, a Novel Selective S1P
    Glaenzel U; Jin Y; Nufer R; Li W; Schroer K; Adam-Stitah S; Peter van Marle S; Legangneux E; Borell H; James AD; Meissner A; Camenisch G; Gardin A
    Drug Metab Dispos; 2018 Jul; 46(7):1001-1013. PubMed ID: 29735753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.